RxDoctor Payments Data

April White, NP

Family · Athens, WVNPI 1114574621

Payments from drug & device makers

$3,253in general payments, 2019–2025

Across 207 payments — averaging $15.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$887
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$441
  • AbbVie$401
  • Teva Pharmaceuticals USA, Inc.$375
  • Lundbeck LLC$312
  • Otsuka America Pharmaceutical, Inc.$255
  • plus $583 from 8 others

What the payments were for

  • Food & beverage$3,18898%
  • Education$662%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,253 in reported general payments places this provider in the 85th percentile of 1,507 family providers in West Virginia.

See all family providers in West Virginia

Medicare billing

Part B allowed, 2024
$24,410
Medicare patients
52
Services billed
373

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate47$169,266
IngrezzaValbenazine Tosylate12$102,545
VraylarCariprazine Hcl21$30,424
Ziprasidone Hcl72$6,020
Aripiprazole85$2,710
Divalproex Sodium ErDivalproex Sodium29$2,703
Quetiapine Fumarate139$2,485
Hydroxyzine Pamoate171$2,230
Lurasidone Hcl33$1,923
Bupropion XlBupropion Hcl52$1,906
Doxepin Hcl83$1,866
Olanzapine36$1,722
Buspirone Hcl183$1,643
Clonazepam175$1,544
Lorazepam152$1,517

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna$887$169,26647 claims
Neurocrine Biosciences, Inc.Ingrezza$143$102,54512 claims
AbbVieVraylar$401$30,42421 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,507 family providers in West Virginia.

Other family in Athens

See the full list for West Virginia

Where these figures come from

Is this you, or does something look wrong? →